Request Trial
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 June 2020Americas

PTAB to review Minnesota patent after Gilead petition

Gilead Sciences has persuaded the US Patent Trial and Appeal Board (PTAB) to review an antiviral patent owned by the  University of Minnesota (UM).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen and subsidiary dealt $20m blow over rodent antibody tech
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Americas
Moderna: BioNTech is claiming work ‘it never did’
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.
Americas
US biotech fires trade secrets suit at Chinese pharma group
10 June 2026   Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026

More features

Exclusive: ‘Cultural differences are an asset’ at the UPC
Amgen and subsidiary dealt $20m blow over rodent antibody tech
Ex-Simmons head of IP joins Carpmaels & Ransford
Moderna: BioNTech is claiming work ‘it never did’
Siemens ordered to recall mammography device across European countries
MoFo bags IP trial duo with 50 years’ combined experience
US biotech fires trade secrets suit at Chinese pharma group
Hikma v Amarin: Six takeaways from the pivotal ruling